title: The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats.
abstract: BACKGROUND
  Activation of peroxisome proliferator-activated receptor (PPAR)gamma is associated with bone loss and increased fracture risk, while PPARalpha activation seems to have positive skeletal effects. To further explore these effects we have examined the effect of the PPARalpha agonists fenofibrate and Wyeth 14643, and the PPARgamma agonist pioglitazone, on bone mineral density (BMD), bone architecture and biomechanical strength in ovariectomized rats.
  
  
  METHODS
  Fifty-five female Sprague-Dawley rats were assigned to five groups. One group was sham-operated and given vehicle (methylcellulose), the other groups were ovariectomized and given vehicle, fenofibrate, Wyeth 14643 and pioglitazone, respectively, daily for four months. Whole body and femoral BMD were measured by dual X-ray absorptiometry (DXA), and biomechanical testing of femurs, and micro-computed tomography (microCT) of the femoral shaft and head, were performed.
  
  
  RESULTS
  Whole body and femoral BMD were significantly higher in sham controls and ovariectomized animals given fenofibrate, compared to ovariectomized controls. Ovariectomized rats given Wyeth 14643, maintained whole body BMD at sham levels, while rats on pioglitazone had lower whole body and femoral BMD, impaired bone quality and less mechanical strength compared to sham and ovariectomized controls. In contrast, cortical volume, trabecular bone volume and thickness, and endocortical volume were maintained at sham levels in rats given fenofibrate.
  
  
  CONCLUSIONS
  The PPARalpha agonist fenofibrate, and to a lesser extent the PPARaplha agonist Wyeth 14643, maintained BMD and bone architecture at sham levels, while the PPARgamma agonist pioglitazone exaggerated bone loss and negatively affected bone architecture, in ovariectomized rats.
authors: Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway. kamilla.stunes@ntnu.no.
authors: Astrid K
authors: AK
authors: Stunes
authors: Irene
authors: I
authors: Westbroek
authors: Björn I
authors: BI
authors: Gustafsson
authors: Reidar
authors: R
authors: Fossmark
authors: Jan H
authors: JH
authors: Waarsing
authors: Erik F
authors: EF
authors: Eriksen
authors: Christiane
authors: C
authors: Petzold
authors: Janne E
authors: JE
authors: Reseland
authors: Unni
authors: U
authors: Syversen
references: Obes Res. 2004 Jun;12(6):962-71
references: 15229336
references: Carcinogenesis. 1987 May;8(5):631-6
references: 3555880
references: Diabetes Care. 2002 Apr;25(4):708-11
references: 11919129
references: BMJ. 2010 Sep 06;341:c4848
references: 20819889
references: Life Sci. 2006 Nov 2;79(23):2209-16
references: 16904700
references: J Cell Biochem. 1999 Sep 1;74(3):357-71
references: 10412038
references: Calcif Tissue Int. 2008 Oct;83(4):285-92
references: 18836674
references: J Biol Chem. 2000 May 12;275(19):14388-93
references: 10799521
references: Am J Hypertens. 2007 Feb;20(2):206-10
references: 17261469
references: Diabetes. 1996 Dec;45(12):1661-9
references: 8922349
references: J Bone Miner Res. 2008 Jan;23(1):17-29
references: 17784844
references: Diabetes Care. 2005 Jul;28(7):1547-54
references: 15983299
references: J Lab Clin Med. 2003 Jul;142(1):29-34
references: 12878983
references: Comput Methods Biomech Biomed Engin. 1997;1(1):15-23
references: 11264794
references: Diabetes Obes Metab. 2008 May;10(5):367-75
references: 17645557
references: J Biol Chem. 2003 Jun 27;278(26):23270-7
references: 12704187
references: Diabetes Care. 2007 Jun;30(6):1574-6
references: 17363747
references: Clin Exp Rheumatol. 2005 May-Jun;23(3):323-30
references: 15971419
references: Clin Ther. 2006 May;28(5):679-88
references: 16861090
references: FEBS Lett. 2000 Apr 7;471(1):119-24
references: 10760525
references: Osteoporos Int. 2008 Feb;19(2):129-37
references: 17901911
references: BMC Endocr Disord. 2009 Mar 30;9:10
references: 19331671
references: Trends Pharmacol Sci. 2005 May;26(5):244-51
references: 15860371
references: J Clin Endocrinol Metab. 2006 Sep;91(9):3349-54
references: 16608888
references: N Engl J Med. 2006 Dec 7;355(23):2427-43
references: 17145742
references: Methods Mol Biol. 2008;455:111-24
references: 18463814
references: J Clin Invest. 2004 Mar;113(6):846-55
references: 15067317
references: Endocrinology. 2002 Jun;143(6):2376-84
references: 12021203
references: Biochem J. 2006 Jan 1;393(Pt 1):7-20
references: 16336196
references: Endocrinology. 2004 Jan;145(1):401-6
references: 14500573
references: Ann N Y Acad Sci. 1996 Dec 27;804:231-51
references: 8993547
references: J Bone Miner Metab. 2005;23(4):275-9
references: 15981022
references: Endocrinology. 1999 Nov;140(11):5060-5
references: 10537132
references: PPAR Res. 2006;2006:24502
references: 17259663
references: Life Sci. 2008 Mar 12;82(11-12):561-9
references: 18272184
references: BMC Dev Biol. 2008 Jul 14;8:71
references: 18625072
references: Obes Surg. 2008 Sep;18(9):1134-43
references: 18563500
references: Fundam Clin Pharmacol. 2007 Jun;21(3):231-44
references: 17521292
references: Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2443-8
references: 11226258
references: Int J Obes Relat Metab Disord. 2004 May;28(5):719-25
references: 15007394
references: Osteoporos Int. 2008 May;19(5):595-606
references: 17965817
references: Bone. 2006 Oct;39(4):796-806
references: 16759917
references: J Bone Miner Res. 1994 May;9(5):679-85
references: 8053397
references: Ann Pharmacother. 2007 Jun;41(6):973-83
references: 17519293
references: Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4312-7
references: 9113986
references: J Cell Biochem. 2002;85(4):825-36
references: 11968022
references: Endocrinology. 2005 Mar;146(3):1226-35
references: 15591153
references: Bone. 2007 Jan;40(1):149-59
references: 17010686
references: Annu Rev Med. 2002;53:409-35
references: 11818483
references: Bone. 1993 Mar-Apr;14(2):173-82
references: 8334036
references: Thromb Haemost. 2007 May;97(5):868-70
references: 17479201
references: Peptides. 2004 Mar;25(3):331-8
references: 15134858
references: Nature. 1990 Oct 18;347(6294):645-50
references: 2129546
references: Mol Pharmacol. 1996 Nov;50(5):1087-94
references: 8913339
references: Methods Mol Med. 2003;80:29-39
references: 12728708
references: Biochem Biophys Res Commun. 2006 Jan 27;339(4):1190-6
references: 16338222
references: Bone. 2004 Oct;35(4):842-9
references: 15454091
references: J Clin Endocrinol Metab. 2001 May;86(5):1930-5
references: 11344187
references: J Cell Biochem. 2007 May 15;101(2):360-8
references: 17163489
references: Calcif Tissue Int. 1999 Nov;65(5):411-3
references: 10541770
references: Nat Med. 2007 Dec;13(12):1496-503
references: 18059282
references: J Cell Biochem. 2006 Sep 1;99(1):196-208
references: 16598753
references: J Bone Miner Res. 2001 Aug;16(8):1426-33
references: 11499865
references: Calcif Tissue Int. 2004 Oct;75(4):329-37
references: 15549648
references: J Clin Endocrinol Metab. 2007 Apr;92(4):1305-10
references: 17264176
references: Biochem Biophys Res Commun. 2004 Nov 5;324(1):92-7
references: 15464987
references: J Nutr. 2005 Oct;135(10):2399-404
references: 16177203
references: PLoS One. 2008 Jul 02;3(7):e2540
references: 18648530
references: J Endocrinol. 2004 Oct;183(1):203-16
references: 15525588
references: Bone. 2008 Apr;42(4):765-74
references: 18242157
references: J Clin Endocrinol Metab. 2005 Dec;90(12):6508-15
references: 16189253
references: Osteoporos Int. 2005 Mar;16 Suppl 2:S25-35
references: 15340800
references: N Engl J Med. 2006 May 25;354(21):2250-61
references: 16723616
references: Pharmacol Rev. 2006 Dec;58(4):726-41
references: 17132851
references: Biochem Biophys Res Commun. 2002 Jan 25;290(3):1114-22
references: 11798191
references: Endocrinology. 2007 Jun;148(6):2669-80
references: 17332064